Novartis | NVS - Equity Capital And Reserves


Novartis reported $37.56B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -4.58B 1.35B Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
Bausch Health Companies USD -341M 461M Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Canopy Growth CAD 688.63M 8.96M Jun/2026
Corcept Therapeutics USD 833.74M 127.96M Sep/2026
Drreddys Laboratories INR 389.37B 8.91B Sep/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
Glaxosmithkline GBP 18.36B 940M Sep/2026
J&J USD 81.53B 3.44B Sep/2026
Merck USD 44.89B 2.96B Sep/2026
Novartis USD 37.23B 4.72B Sep/2026
Novartis USD 37.56B 1.36B Sep/2026
Pacira USD 712.32M 40.34M Sep/2026
Perrigo USD 2.44B 75.4M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Phibro Animal Health USD 417.67M 32.19M Sep/2026
Prestige Brands USD 1.94B 27.95M Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 72.88B 3.31B Sep/2026
Sanofi EUR 69.57B 3.58B Jun/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
Zoetis USD 3.3B 155M Sep/2026